Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

Slamon et al. (Wed,) studied this question.

www.synapsesocial.com/papers/69d8d9b0d2f7327e70ae46b1 — DOI: https://doi.org/10.1056/nejmoa1911149

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer· 2019 · 1,016 citations
2. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer· 2018 · 1,284 citations
3. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3· 2018 · 1,099 citations
4. Evolving options for the treatment of metastatic breast cancer: Progression-free survival as an endpoint· 2011 · 19 citations
5. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro· 2009 · 1,401 citations